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Abstract
Acute ischemic stroke is the third leading cause of death in industrialized countries and the most
frequent cause of permanent disability in adults worldwide. Despite advances in the understanding
of the pathophysiology of cerebral ischemia, therapeutic options remain limited. Only recombinant
tissue-plasminogen activator (rt-PA) for thrombolysis is currently approved for use in the
treatment of this devastating disease. However, its use is limited by its short therapeutic window
(three hours), complications derived essentially from the risk of hemorrhage, and the potential
damage from reperfusion/ischemic injury. Two important pathophysiological mechanisms involved
during ischemic stroke are oxidative stress and inflammation. Brain tissue is not well equipped with
antioxidant defenses, so reactive oxygen species and other free radicals/oxidants, released by
inflammatory cells, threaten tissue viability in the vicinity of the ischemic core. This review will
discuss the molecular aspects of oxidative stress and inflammation in ischemic stroke and potential
therapeutic strategies that target neuroinflammation and the innate immune system. Currently,
little is known about endogenous counterregulatory immune mechanisms. However, recent studies
showing that regulatory T cells are major cerebroprotective immunomodulators after stroke
suggest that targeting the endogenous adaptive immune response may offer novel promising
neuroprotectant therapies.
Introduction
Stroke is the third leading cause of death in industrialized
countries [1] and the most frequent cause of permanent
disability in adults worldwide [2]. Three months follow-
ing a stroke, 15-30% of stroke survivors are permanently
disabled and 20% require institutional care [3]. Deficits
can include partial paralysis, difficulties with memory,
thinking, language, and movements. In the Western
world, over 70% of individuals experiencing a stroke are
over 65 years of age. Since life expectancy continues to
grow, the absolute number of individuals with stroke will
further increase in the future.
The most common cause of stroke is the sudden occlusion
of a blood vessel by a thrombus or embolism, resulting in
an almost immediate loss of oxygen and glucose to the
cerebral tissue. Although different mechanisms are
involved in the pathogenesis of stroke, increasing evi-
dence shows that ischemic injury and inflammation
account for its pathogenic progression [4]. Cerebral
ischemia triggers the pathological pathways of the
ischemic cascade and ultimately causes irreversible neuro-
nal injury in the ischemic core within minutes of the onset
[5].
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However, a much larger volume of brain tissue surround-
ing this ischemic core, known as the penumbra, can be
salvaged if cerebral blood flow is promptly restored. Thus,
the original definition of the ischemic penumbra referred
to areas of brain that were damaged but not yet dead,
offering the promise that if proper therapies could be
found, one could rescue brain tissue after stroke and
reduce post-stroke disability.
Despite advances in the understanding of the pathophys-
iology of cerebral ischemia, therapeutic options for acute
ischemic stroke remain very limited [2]. Only one drug is
approved for clinical use for the thrombolytic treatment
of acute ischemic stroke in the US and that is intravenous
recombinant tissue plasminogen activator (rt-PA). When
delivered within three hours after symptom onset, rt-PA
reduces neurological deficits and improves the functional
outcome of stroke patients. However, this improvement
in recovery is achieved at the expense of an increased inci-
dence in symptomatic intracranial hemorrhage, which
occurs in ~6% of patients. Furthermore, since the large
majority of patients with acute ischemic stroke do not go
to the hospital within three hours of stroke onset most do
not receive rt-PA treatment [6]. Consequently, the success-
ful treatment of acute ischemic stroke remains one of the
major challenges in clinical medicine.
This review will provide a brief overview of the current
understanding of the inflammatory mechanisms involved
in an acute ischemic stroke and the neuroprotective agents
that can curtail neuroinflammation and potentially show
utility in the treatment of stroke. Neuroprotective treat-
ments are therapies that block the cellular, biochemical,
and metabolic elaboration of injury during exposure to
ischemia. Of the more than 100 neuroprotective agents
that reached randomized clinical trials in focal ischemic
stroke, none has proven unequivocally efficacious,
despite success seen in preceding animal studies [7]. How-
ever, the failed trials of the past have greatly increased our
understanding of the fundamental biology of ischemic
brain injury and have laid a strong foundation for future
advance. New anti-inflammatory targets continue to be
identified, which is an important area for translational
medicine in acute stroke. Overall, the prospects for safe
neuroprotective therapies to improve stroke outcome
remain promising [8]
Ischemic cascade
Acute ischemic stroke accounts for about 85% of all cases
while hemorrhagic stroke is responsible for almost 15%
of all strokes. Ischemic stroke results from the sudden
decrease or loss of blood circulation to an area of the
brain, resulting in a corresponding loss of neurological
function. It is a nonspecific term encompassing a hetero-
geneous group of etiologies including thrombosis, embo-
lism, and relative hypoperfusion. In most cases, the cause
is atherothrombosis of large cervical or intracranial arter-
ies, or embolism from the heart.
Within seconds to minutes after the loss of blood flow to
a region of the brain, the ischemic cascade is rapidly initi-
ated, which comprises a series of subsequent biochemical
events that eventually lead to disintegration of cell mem-
branes and neuronal death at the center/core of the infarc-
tion. Ischemic stroke begins with severe focal
hypoperfusion, that leads to excitotoxicity and oxidative
damage which in turn cause microvascular injury, blood-
brain barrier dysfunction and initiate post-ischemic
inflammation. These events all exacerbate the initial
injury and can lead to permanent cerebral damage (see
Figure 1). The amount of permanent damage depends on
several factors: the degree and the duration of ischemia
and the capability of the brain to recover and repair itself
[5].
As a result of residual perfusion from the collateral blood
vessels, regions where blood flow drops to approximately
30 ml/100 g/min ischemic cascade progresses at a slower
rate. Neuronal cells may tolerate this level of reduced (20-
40% of control values) blood flow for several hours from
the stroke onset with full recovery of function following
restoration of blood flow [9].
In the center of the ischemic region cells undergo anoxic
depolarization and they never repolarize. While in the
Ischemic cascade leading to cerebral damage Figure 1
Ischemic cascade leading to cerebral damage. 
Ischemic stroke leads to hypoperfusion of a brain area that 
initiates a complex series of events. Excitotoxicity, oxidative 
stress, microvascular injury, blood-brain barrier dysfunction 
and postischemic inflammation lead ultimately to cell death of 
neurons, glia and endothelial cells. The degree and duration 
of ischemia determines the extent of cerebral damage.
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penumbral region, the cells can repolarize at the expense
of further energy consumption and depolarize again in
response to elevated levels of extracellular glutamate and
potassium ions. Such repetitive depolarizations called
"peri-infarct depolarizations" lead to the increased release
of the excitatory neurotransmitter glutamate with result-
ing excitotoxic cell damage [10]. Ultimately, the severity
of functional and structural changes in the brain caused
by ischemia will depend on its degree and duration.
Hyperbaric (HBO) and normobaric oxygen (NBO) thera-
pies attempt to increase the partial pressure of oxygen to
the tissue and thereby limit the damage caused by hypop-
erfusion. However, three clinical trials of hyperbaric oxy-
gen therapy failed to show efficacy [11]. Normobaric,
high-flow oxygen therapy was shown to cause a transient
improvement of clinical deficits and MRI abnormalities in
a sub-group of patients with acute ischemic stroke. Fur-
ther studies are needed to investigate the safety and effi-
cacy of hyperoxia as a stroke therapy [12].
Oxidative stress
Oxidative stress contributes to the pathogenesis of a
number of neurological conditions including stroke. Oxi-
dative stress is defined as the condition occurring when
the physiological balance between oxidants and antioxi-
dants is disrupted in favor of the former with potential
damage for the organism. Oxidative stress leading to
ischemic cell death involves the formation of ROS/reac-
tive nitrogen species through multiple injury mecha-
nisms, such as mitochondrial inhibition, Ca2+ overload,
reperfusion injury, and inflammation [13]. Plenty of ROS
are generated during an acute ischemic stroke and there is
considerable evidence that oxidative stress is an important
mediator of tissue injury in acute ischemic stroke [14].
Brain ischemia generates superoxide (O2
-), which is the
primary radical from which hydrogen peroxide is formed.
Hydrogen peroxide is the source of hydroxyl radical
(OH). Nitric oxide is a water- and lipid-soluble free radi-
cal that is produced from L-arginine by three types of
nitric oxide synthases (NOS). Ischemia causes an increase
in NOS type I and III activity in neurons and vascular
endothelium, respectively. At a later stage, elevated NOS
type II (iNOS) activity occurs in a range of cells including
glia and infiltrating neutrophils. Thus, free radicals are
regarded as an important therapeutic target for improving
the outcome of an ischemic stroke. Several compounds
with significant antioxidant properties including ebselen
[15], and resveratrol [16], a natural phytoalexin found in
some dietary sources such as grapes and red wine, have
been demonstrated to reduce stroke-related brain damage
in animal models.
The transcription factor Nrf2
Nuclear factor erythroid-related factor 2 (Nrf2) is a tran-
scription factor that regulates an expansive set of antioxi-
dant genes that act in synergy to remove ROS through
sequential enzymatic reactions [17].
Nrf2 gene targets, collectively referred to as phase II genes,
are involved in free radical scavenging, detoxification of
xenobiotics, and maintenance of redox potential. Nrf2 is
normally localized to the cytoplasm, tethered to the regu-
latory protein, kelch-like erythroid cell-derived protein
with CNC homology associated protein 1 (Keap1) (Figure
2). Oxidative stress, or electrophilic agents that mimic oxi-
dative stress, can modify key sulfhydryl group interactions
in the Keap-Nrf2 complex, allowing dissociation and
nuclear translocation of Nrf2. When activated, Nrf2 spe-
cifically targets genes bearing an antioxidant response ele-
ment (ARE) within their promoters such as heme
oxygenase 1, 1-ferritin, and glutathione peroxidase, which
maintain redox homeostasis and influence the inflamma-
tory response. Wide ranges of natural and synthetic small
molecules are potent inducers of Nrf2 activity. These mol-
ecules have been identified from diverse chemical back-
grounds including isothiocyanates, which are abundant
in cruciferous vegetables, heavy metals, and hydroperox-
ides.
Nuclear erythroid-related factor 2 (Nrf2) anti-oxidant signal- ing in acute ischemic stroke Figure 2
Nuclear erythroid-related factor 2 (Nrf2) anti-oxi-
dant signaling in acute ischemic stroke. Nrf2 is the 
principal transcription factor that regulates antioxidant 
response element (ARE)-mediated expression of phase II 
detoxifying antioxidant enzymes. Under normal conditions, 
Nrf2 is sequestered in the cytoplasm by an actin-binding 
(Kelch-like) protein (Keap1); on exposure of cells to oxida-
tive stress, Nrf2 dissociates from Keap1, translocates into 
the nucleus, binds to ARE, and transactivates phase II detoxi-
fying and antioxidant genes. Among the spectrum of antioxi-
dant genes controlled by Nrf2 are catalase, superoxide 
dismutase (SOD), glutathione reductase, and glutathione per-
oxidase.Journal of Translational Medicine 2009, 7:97 http://www.translational-medicine.com/content/7/1/97
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Several studies have shown that increasing Nrf2 activity is
highly neuroprotective in in vitro models that stimulate
components of stroke damage, such as oxidative gluta-
mate toxicity, H2O2 exposure, and Ca2+ overload [18].
Administration of the well characterized Nrf2 inducer,
tert-butylhydroquinone (tBHQ), a metabolite of the
widely used food antioxidant butylated hydroxyanisole,
significantly improved sensorimotor and histological out-
come in two models of I/R in rats and mice [19]. Within
this injury paradigm, Nrf2 activation before stroke was
able to salvage the cortical penumbra but not the stroke
core. Clear differences in stroke outcome were found as
early as 24 hours after reperfusion. Moreover, prophylac-
tic treatment improved functional recovery up to one
month after transient MCAO suggesting that previous
Nrf2 activation may reduce neuronal cell death during
delayed apoptosis and inflammation long after stroke
onset.
Conversely, Nrf2-deficient mice are significantly more
prone to ischemic brain injury and neurological deficits
than WT mice. Deletion of the Nrf2 gene renders animals
more susceptible to various stressors mainly because of
the failure to induce phase II enzymes. Furthermore, an
Nrf2 inducer was able to reverse neuronal cell death
induced by the free radical donor tert-butylhydroperoxide
(t-BuOOH) [19]. The MCAO and reperfusion model is
known to induce a transient focal ischemic cascade that
uniquely includes a substantial surge of free radical dam-
age.
Ischemia/reperfusion (I/R) injury
The ischemic cascade usually goes on for hours but can
last for days, even after restoration of blood circulation.
Although reperfusion of ischemic brain tissue is critical
for restoring normal function, it can paradoxically result
in secondary damage, called ischemia/reperfusion (I/R)
injury.
The definitive pathophysiology regarding I/R injury still
remains obscure; however, oxidative stress mediators such
as reactive oxygen species (ROS) released by inflamma-
tory cells around the I/R injured areas are suggested to
play a critical role [20]. The increase in oxygen free radi-
cals triggers the expression of a number of pro-inflamma-
tory genes by inducing the synthesis of transcription
factors, including NF-κB, hypoxia inducible factor 1,
interferon regulator factor 1 and STAT3. As a result,
cytokines are upregulated in the cerebral tissue and conse-
quently, the expression of adhesion molecules on the
endothelial cell surface is induced, including intercellular
adhesion molecule 1 (ICAM-1), P-selectin and E-selectin
which mediate adhesion of leukocytes to endothelia in
the periphery of the infarct [21].
Furthermore, the complement cascade has been shown to
play a critical role in I/R injury [22]. In addition to direct
cell damage, regional brain I/R induces an inflammatory
response involving complement activation and genera-
tion of active fragments such as C3a and C5a anaphylatox-
ins. Expression of C3a and complement 5a receptors was
found to be significantly increased after middle cerebral
artery occlusion (MCAO) in the mouse indicating an
active role of the complement system in cerebral ischemic
injury. Complement inhibition resulted in neuroprotec-
tion in animal models of stroke [23].
Post-ischemic inflammation
Although for many years the CNS was considered an
immune-privileged organ, it is now well accepted that the
immune and the nervous system are engaged in bi-direc-
tional crosstalk. Moreover, mounting data suggest that in
the brain, as in peripheral organs, inflammatory cells par-
ticipate in tissue remodeling after injury.
Microglial cells are the resident macrophages of the brain
and play a critical role as resident immunocompetent and
phagocytic cells in the CNS. Ekdahl and colleagues [24]
reported an increased number of activated microglial cells
up to 16 weeks after two hour MCAO in rats. After activa-
tion by ischemia, microglia can transform into phagocytes
and they can release a variety of substances many of which
are cytotoxic and/or cytoprotective. Microglia may exert
neuroprotection by producing neurotrophic molecules
such as brain-derived neurotrophic factor (BDNF), insu-
lin-like growth factor I (IGF-I), and several other growth
factors. There is substantial evidence that activated micro-
glial cells in response to ischemia have the potential of
releasing several pro-inflammatory cytokines such as TNF-
α, IL-1β, and IL-6, as well as other potential cytotoxic mol-
ecules including NO, ROS, and prostanoids [25].
Astrocytes, like microglia, are capable of secreting inflam-
matory factors such as cytokines, chemokines, and NO
[26]. Cytokines upregulate the expression of cell adhesion
molecules (CAMs). Within four to six hours after ischemia
onset, circulating leukocytes adhere to vessel walls and
migrate into the brain with subsequent release of addi-
tional pro-inflammatory mediators and secondary injury
in the penumbra. Neutrophils are the earliest leukocyte
subtype to show substantial upregulation in gene expres-
sion studies and to infiltrate areas of brain ischemia (see
below). Recently, Shichita et al. [27] demonstrated an
infiltration of γdT cells 3 days after the onset of ischemia
in a mouse model, along with a production of IL-17
which amplify the inflammatory cascade. IL-23 from infil-
trating macrophages appear to produce Il-23 which
attracts the infiltrating γdT cells. Blocking a specific γdT
cell receptor with an antibody effectively reduced three-
day infarct volumes, even when treatment was initiated atJournal of Translational Medicine 2009, 7:97 http://www.translational-medicine.com/content/7/1/97
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24 hours after onset of cerebral ischemia. Targeting these
γdT cells may offer a clinical opportunity with a longer
therapeutic window to prevent the secondary inflamma-
tory expansion of cerebral damage after stroke.
The described post-ischemic neuroinflammatory changes
lead to dysfunction of the blood-brain barrier, cerebral
edema, and neuronal cell death (summarized in Figure 3).
Therefore, therapeutic targeting of the neuroinflammatory
pathways in acute ischemic stroke has become an impor-
tant area of research in translational medicine.
Cytokines and brain inflammation
Cytokines are a group of small glycoproteins that are pro-
duced in response to an antigen and were originally
described as mediators for regulating the innate and adap-
tive immune systems. Cytokines are thus upregulated in
the brain in a variety of diseases, including stroke. In the
brain, cytokines are expressed not only in the cells of the
immune system, but are also produced by resident brain
cells, including neurons and glia [28]. In addition, it has
been shown that peripherally derived cytokines are
involved in brain inflammation. Thus, peripherally
derived mononuclear phagocytes, T lymphocytes, NK
cells and polymorphonuclear leukocytes produce and
secrete cytokines and might contribute to inflammation
of the CNS [29].
The most studied cytokines related to inflammation in
acute ischemic stroke are tumor necrosis factor-α (TNF-α),
the interleukins (IL), IL-1β, IL-6, IL-20, IL-10 and trans-
forming growth factor (TGF)-β. While IL-1β and TNF-α,
appear to exacerbate cerebral injury, TGF-β and IL-10 may
be neuroprotective [30,31]. Increased production of pro-
inflammatory cytokines and lower levels of the anti-
inflammatory IL-10 are related to larger infarctions and
poorer clinical outcome.
Elevated IL-1β mRNA expression occurs within the first
15-30 min after permanent MCAO and elevated IL-1β
protein expression occurs a few hours later and remains
elevated for up to 4 days [32]. There are studies that corre-
late an increase in the levels of IL-1β after ischemia with
worsening of the infarct severity. For example, Yamasaki
et al [33] demonstrated that intraventricular injection of
recombinant IL-1β after MCAO increases the formation of
brain edema, the volume of the size and the influx of neu-
trophils. In addition, IL-1β deficient mice presented
smaller infarcts in comparison with wild-type mice [34].
High circulating IL-1β elevates circulating IL-6, another
well known cytokine that is upregulated following cere-
bral ischemia [35]. Moreover, the serum level of IL-6 cor-
relates with brain infarct volume [36] and is a powerful
predictor of early neurological deterioration [37]. On the
other hand, Clark et al [38] demonstrated that infarct size
and neurological function were not different in animals
deficient in IL-6 after transient CNS ischemia. This sug-
gests that IL-6 does not have a direct influence on acute
ischemic injury.
IL-20 is induced when IL-1β modulates p38 MAPK and
the NF-κB pathway. IL-20 in turn induces the production
of IL-6. Inhibition of IL-20 by a specific mAb significantly
ameliorated the brain ischemic infarction in rats follow-
ing MCAO [39].
Several approaches are under investigation for managing
IL-1 in stroke (Table 1). IL-1 acts via membrane receptors
(IL-1R), which can be blocked by a receptor antagonist
(IL-1RA). In a randomized trial for acute stroke, IL-1RA
readily crossed the blood-brain barrier, was safe to use,
and seemed to afford some benefit, particularly for
patients with cortical infarcts [40].
IL-10 is an anti-inflammatory cytokine that acts by inhib-
iting IL-1 and TNF-α, and by suppressing cytokine recep-
tor expression and receptor activation as well. As a
consequence, IL-10 could provide neuroprotection in
Postischemic inflammatory response Figure 3
Postischemic inflammatory response. Excitotoxicity 
and oxidative stress caused by the initial ischemic event acti-
vate microglia and astrocytes which react by secreting 
cytokines, chemokines and matrix metalloproteases (MMP). 
These inflammatory mediators lead to an upregulation of cell 
adhesion molecules on endothelial cells, allowing blood-
derived inflammatory cells, mainly neutrophils, to infiltrate 
the ischemic brain area. Neutrophils themselves also secrete 
cytokines which cause a further activation of glial cells. These 
processes all result in neuronal cell death and enhance the 
damage to the ischemic brain.
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acute ischemic stroke. Both central and systemic adminis-
tration of IL-10 to rats subjected to MCAO significantly
reduced infarct size 30 min to three hours post MCAO
[30]. In acute ischemic stroke, elevated concentrations of
IL-10 in CSF have been found [41]. Moreover, patients
with low plasma levels (<6 pg/ml) of IL-10 during the first
hours after stroke were three times more likely to have
worsening neurological symptoms within 48 hours fol-
lowing the stroke [37]. IL-10 also seems to mediate the
reduction in infarct size by regulatory T cells (see below).
Chemokines and brain inflammation
Chemokines, for example, monocyte chemoattractant
protein 1, are a class of cytokines that guide the migration
of blood borne inflammatory cells, such as neutrophils
and macrophages, towards the source of the chemokine.
Consequently, they play important roles in cellular com-
munication and inflammatory cell recruitment. Expres-
sion of chemokines such as MCP-1, macrophage
inflammatory protein-1α (MIP-1α), and fractakline fol-
lowing focal ischemia is thought to have a deleterious
effect by increasing leukocyte infiltration [42]. The level of
a variety of chemokines has been found to increase in ani-
mal models of ischemia and their inhibition or deficiency
has been associated with reduced injury [43-45]. Mice
without the chemokine receptor CCR2 are protected
against ischemia-reperfusion injury [46].
Cellular adhesion molecules
There is increasing evidence that cellular adhesion mole-
cules (CAMs) play an important role in the pathophysiol-
ogy of acute ischemic stroke [21]. CAMs are upregulated
in the first days after stroke by various cytokines and are
responsible for the adhesion and migration of the leuko-
cytes. Leukocytes roll on the endothelial surface and then
adhere to the endothelial cells. The interaction between
leukocytes and the vascular endothelium is mediated by
three main groups of CAMs: the selectins, the immu-
noglobulin gene superfamily, and the integrins. Selectins,
especially E- and P-selectins are upregulated and mediate
leukocyte rolling and recruitment during the early stages
of ischemia [47] Among the immunoglobulin family
member, intercellular adhesions molecule-1 (ICAM-1)
and vascular cell adhesion molecule-1 have been the most
extensively investigated in cerebral ischemia. Within
hours after stroke onset, ICAM-1 expression increases
upon stimulation by cytokines [48].
Patients with acute ischemic stroke had higher soluble
intercellular adhesion molecule-1 (sICAM-1) levels com-
pared to patients without cardiovascular disease. Moreo-
ver, sICAM-1 levels were significantly higher in patients
who died compared to those who survived [49]. High
sICAM-1 levels on admission are associated with early
death is ischemic middle-aged stroke patients suggesting a
pathogenic role of inflammation in the evolution of
ischemic stroke.
A number of animal studies have shown that after tran-
sient and permanent focal ischemia the upregulation of
CAMs, especially ICAM-1, P- and E-selectin, preceded the
invasion of neutrophils into brain. There is ample evi-
Table 1: Clinical studies of agents targeting inflammatory pathways in acute ischemic stroke.
Neuroprotective Agent Mode of Action Reference
Recombinant human IL-1RA Interleukin-1 receptor antagonist [67]
Enlimomab Anti-ICAM-1 monoclonal antibody [68]
Tirilazad Lipid peroxidation inhibitor [69]
UK-279, 276 Neutrophil inhibitory factor [70]
Cerovive (NXY-059) Nitrone-based free radical trapping agent [71,72]
Acetaminophen (Paracetamol) Anti-pyretic effect [73]
Minocycline Anti-inflammatory [74]
Ginsenoside Ca2+ channel antagonist [75]
Edaravone MCI-186 Free radical scavenger [76]
ONO-2506 (Arundic Acid) Astrocyte modulator [77]
Adapted from Shah et al., 2009 [78].Journal of Translational Medicine 2009, 7:97 http://www.translational-medicine.com/content/7/1/97
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dence from animal models of MCAO that expression of
CAMs is associated with cerebral infarct size. Thus, genetic
ablation of CAMs resulted in reduced infarct size, which
could be mimicked by treatment with anti-CAM antibod-
ies [50,51]. Inhibition of leukocyte activation and infiltra-
tion into the ischemic cerebral tissue has, therefore, been
an important area of neuroprotection research. Thus far,
anti-CAM treatment has not been successful in patients
with acute ischemic stroke. However, further translational
research into the therapeutic targeting of CAM is ongoing.
The spatiotemporal profile of CAMs is still largely unre-
solved, even though they are crucial for efficient anti-
inflammatory therapies. More knowledge of the spatio-
temporal profile of CAMs may lead the way to successful
application and monitoring of promising anti-inflamma-
tory treatment strategies after stroke.
Matrix metalloproteinases
MMPs are a family of proteolytic enzymes that are respon-
sible for remodeling the extracellular matrix and that can
degrade all its constituents. Expression of MMPs in the
adult brain is very low to undetectable, but many MMPs
are upregulated in the brain in response to injury [52].
Neurons, astrocytes, microglia, and endothelial cells have
all been shown to express MMPs after injury. Stroke is
associated with a biphasic disruption of the blood brain
barrier (BBB) leading to vasogenic edema and hemor-
rhage and experimental studies have shown that that BBB
breakdown and hemorrhage results from the expression
and activation of MMPs [53].
MMP-2 and MMP-9 have been implicated in cerebral
ischemia. Elevated MMP-9 levels were found in brain tis-
sue and in serum from patients with acute ischemic stroke
and in animal models of stroke beginning at 12 h after
permanent MCAO [54]. MMP-9 is normally absent and
this is the major MMP associated with neuroinflamma-
tion. Early (day 1) MMP-9 inhibition reduced infarction
of day 14. However, benefit was lost when the treatment
was delayed until day 3 and stroke pathology was exacer-
bated when administration was delayed until day 7 [55].
These studies all suggest that MMP inhibition could have
a beneficial effect on the outcome of stroke but the effect
will depend on the timing of treatment in relation to the
stage of brain injury [55].
Regulatory T lymphocytes
Severe brain ischemia also perturbs innate and adaptive
immune cells, resulting in systemic immunodepression
that predisposes patients after stroke to life-threatening
infections [56]. Postischemic alterations in the immune
system might represent a useful immunomodulatory
adaptation, preventing autoimmune reactions against
CNS antigens after stroke.
Recently, regulatory T lymphocytes (Treg) were shown to
play an important role in protecting cells in a mouse
model for stroke [57]. Thymus-derived CD4+CD25+Foxp3
Treg cells play a key part in controlling immune responses
under physiological conditions and in various systemic
and CNS inflammatory diseases [58]. Treg are generated by
dendritic or antigen-presenting cells expressing the immu-
nosuppressive mediator indoleamine 2,3-dioxygenase,
the first enzyme in the kynurenine pathway, that degrades
and converts tryptophan to kynurenine [59]. Interferon-γ
and TNF-α which are both present at high levels in the
ischemic brain induce IDO in response to chronic
immune activation, possibly in microglia [60].
A stroke in mice with no functioning Treg cells in their
blood caused much greater damage to the brain and
greater disabilities than in animals with functioning Treg
cells. Treg cells protect cells by suppressing the harmful
activation of the immune system and can thus also pre-
vent autoimmune diseases from developing. IL-10 is a
cytokine that is produced by the Treg cells and seems to
play an important role during a stroke. Mice with no func-
tioning Treg cells that were injected with IL-10 on the first
day following a stroke had markedly less brain damage
than mice that did not receive IL-10. On the other hand,
the transfer of genetically modified Treg cells unable to
produce IL-10 offered no protection [57]. Treg cells pro-
ducing IL-10 induce IDO suggesting that IL-10 may act
upstream by modulating the production of IDO.
Depletion of Treg cells profoundly increased delayed brain
damage and deteriorated functional outcome. Absence of
Treg cells augmented postischemic activation of resident
and invading inflammatory cells including microglia and
T cells, the main sources of cerebral TNF-α and IFN-γ,
respectively. Treg cells prevent secondary infarct growth by
counteracting excessive production of proinflammatory
cytokines and by modulating invasion and/or activation
of lymphocytes and microglia in the ischemic brain. Liesz
et al [57] found that Treg cells antagonize enhanced TNF-α
and IFN-γ production, which induce delayed inflamma-
tory brain damage, and that Treg cell-derived secretion of
IL-10 is the key mediator of the cerebroprotective effect
via suppression of proinflammatory cytokine production.
IL-10 potently reduced infarct size in normal mice and
prevented delayed lesion growth after Treg cells depletion
(Figure 4).
Post-stroke recovery
Patients experiencing a typical large-vessel acute ischemic
stroke will lose 120 million neurons each hour. Com-
pared with the normal rate of neuron loss during aging,
the ischemic brain will age 3.6 years for every hour the
stroke goes untreated. Thus, it is not surprising that the
majority of stroke patients exhibit certain levels of motorJournal of Translational Medicine 2009, 7:97 http://www.translational-medicine.com/content/7/1/97
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weakness and sensory disturbances [2]. However, over
time, most will show a certain degree of functional recov-
ery which may be explained by brain reorganization and
brain plasticity.
Brain plasticity refers to the brain's ability to change its
structure and function during development, learning, and
pathology. For example, within the minutes following
ischemia, rapid changes are observed in the number and
length of dendritic spines of the neurons in the penumbra
region. The initial loss is then followed by the re-establish-
ment of the dendritic spine synapses several months after
the initial stroke as part of the functional recovery process
[61].
Functional MRI studies have demonstrated that the dam-
aged adult brain is able to reorganize to compensate for
motor deficits [62,63]. The main mechanism underlying
recovery of motor abilities appears to involve enhanced
activity in preexisting networks. Studies in experimental
stroke models demonstrate that focal cerebral ischemia
promotes neurogenesis in the subventricular zone (SVZ)
and subgranular zone (SGZ) of the dentate gyrus and
induces SVZ neuroblast migration towards the ischemic
boundary. More importantly, stroke-induced neurogene-
sis has also recently been demonstrated in the adult
human brain, even in advanced age patients [64-66] These
findings have led to a hope for a neurorestorative treat-
ment of stroke which aims to manipulate endogenous
neurogenesis and thereby enhance brain repair.
Conclusion
In conclusion, in the presented work, we sought to pro-
vide a brief overview of the current understanding of
inflammatory mechanisms involved during acute
ischemic stroke and neuroprotective agents that can cur-
tail neuroinflammation and could have utility in the treat-
ment of stroke (see Table 1). As discussed, evidence
suggests that post-ischemic oxidative stress and inflamma-
tion contribute to brain injury and to the expansion of the
ischemic lesion. On the other hand, an adequate adaptive
immune response after acute brain ischemia also plays an
important role in response to ischemic injury as shown by
the tremendous potential of Treg cells to prevent secondary
infarct growth by counteracting the production of proin-
flammatory cytokines and by modulating the activation
of lymphocytes and microglia in the ischemic brain [57].
These results provide new insights into the immun-
opathogenesis of acute ischemic stroke and could lead to
new approaches that involve immune modulation using
Treg cells.
To date, 1,026 drugs have been tested in various animal
models, of which 114 underwent clinical evaluation [8].
The greater part of the agents studied until now have
failed. Consequently, rt-PA remains the only agent shown
to improve stroke outcome in clinical trials, despite the
many clinical trials conducted. However, its use is limited
by its short therapeutic window (three hours), by its com-
plications derived essentially from the risk of hemorrhage,
and by the potential damage by R/I injury. Because of
these drawbacks the optimum treatment of cerebral focal
ischemia remains one of the major challenges in clinical
medicine.
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